Home > Products > All > FOSCARNET Sodium Injection*
Product Image
Please see full prescribing and safety information, including boxed warning, for FOSCARNET premix bags.

Available in:

  • 6,000 mg per 250 mL single-dose premix bags

Benefits:

  • AP Rated
  • Preservative-free
  • DEHP-free
  • PVC-free
  • Not made with natural rubber latex

Downloads:

PreventIV

FOSCARNET Sodium Injection*

Brand Name Equivalent: FOSCAVIR® (FOSCAVIR is a registered trademark of Clinigen Healthcare)
Therapeutic Category: Anti-Infective

PreventIV Measures® Features:

  • Easy-to-read drug name and dosage strength to aid in identifying the right product
  • Bar codes included on the bag, overwrap and carton for ease of scanning
  • Unique label design to help products stand out on the shelf
  • Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
NDC
#25021		 Description Strength Fill
Volume 		Concentration Container
Size 		Closure Unit
of Sale
189-84 Premix Bag 6,000 mg 250 mL 24 mg per mL N/A N/A 10

WARNING

RENAL IMPAIRMENT IS THE MAJOR TOXICITY OF FOSCARNET SODIUM INJECTION. FREQUENT MONITORING OF SERUM CREATININE, WITH DOSE ADJUSTMENT FOR CHANGES IN RENAL FUNCTION, AND ADEQUATE HYDRATION WITH ADMINISTRATION OF FOSCARNET SODIUM INJECTION IS IMPERATIVE. (See ADMINISTRATION section; Hydration.)

SEIZURES, RELATED TO ALTERATIONS IN PLASMA MINERALS AND ELECTROLYTES, HAVE BEEN ASSOCIATED WITH FOSCARNET SODIUM INJECTION TREATMENT. THEREFORE, PATIENTS MUST BE CAREFULLY MONITORED FOR SUCH CHANGES AND THEIR POTENTIAL SEQUELAE. MINERAL AND ELECTROLYTE SUPPLEMENTATION MAY BE REQUIRED. FOSCARNET SODIUM INJECTION IS INDICATED FOR USE ONLY IN IMMUNOCOMPROMISED PATIENTS WITH CMV RETINITIS AND MUCOCUTANEOUS ACYCLOVIR­RESISTANT HSV INFECTIONS. (See INDICATIONS section).